drugset / Trial / NCT05417425

Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers

NCT05417425

Phase 1 Completed 25 enrolled Omeza, LLC
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the efficacy of OCM™ used in combination with off-loading devices for the treatment of diabetic foot ulcers.

Timeline

Start
2022-09-01
Primary completion
2023-10-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified Topical
Subject Omeza skin protectant Unknown Topical

Indications